Low density of sigma-1 receptors in early Alzheimer’s disease.Apr 9, 2008Ann Nucl Med 22, 151-156, (2008).Mishina, M.,Ohyama,M., Ishii, K., Kitamura, S., Kimura,Y.,Oda, K., et al.View abstract in PubMed
Ann Nucl Med 22, 151-156, (2008).Mishina, M.,Ohyama,M., Ishii, K., Kitamura, S., Kimura,Y.,Oda, K., et al.View abstract in PubMed
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
